StockData
BioLineRx Ltd. logo

BioLineRx Ltd. (BLRX) stock

BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.12−0.03 (-2.61%)

Close on Nov 17, 2026Market cap $4.87MP/E –Yield –

BioLineRx ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was -$9.76M. The highest annual figure on record is -$9.76M in fiscal 2025.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$9.76M–
FY2024Dec 31, 2024-$16.34M–
FY2023Dec 31, 2023-$48.31M–
FY2022Dec 31, 2022-$28.50M–
FY2021Dec 31, 2021-$24.07M–
FY2020Dec 31, 2020-$21.99M–
FY2019Dec 31, 2019-$27.17M–
FY2018Dec 31, 2018-$25.06M–
FY2017Dec 31, 2017-$24.76M–
FY2016Dec 31, 2016-$16.03M–
FY2015Dec 31, 2015-$15.76M–

More BioLineRx figures

See a number that looks wrong?